Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Aldevron and Integrated DNA Technologies (IDT), both Danaher companies, announced on November 4, 2026, the launch of
"The challenge is not simply to make more editing tools available—it is to bring the right capabilities together around the problems researchers need to solve," said
For prime editing, the companies developed PE Ultra mRNAs, which feature an engineered prime editor. They pair these with chemically modified Alt-R prime editing guide RNAs (pegRNAs) that contain a proprietary modification pattern designed to enhance editing performance.¹ IDT also released a bioinformatics tool for
For base editing, the companies now offer 6 stocked ABE8e-based mRNA variants spanning different protospacer adjacent motif (PAM) compatibilities and fidelity profiles, plus a screening kit for evaluating all 6 editors in parallel.¹ IDT has also released Alt-R CRISPR-Cas9 sgRNA XT, a clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 single guide RNA (sgRNA) product, for use in base editing and Cas9-mediated workflows using mRNA.¹ The stocked base and prime editing mRNA products are available at scales of 20 µg to 1 mg, with larger scales available from Aldevron through custom orders.¹
Base editing enables a
According to the companies, prime editing often struggles to reach efficient editing rates across targets and cell types.¹ Base editing can be limited by PAM restrictions and variable editor activity. Those limits can reduce the number of targetable sites and make it difficult to identify the optimal editor for a given application.¹
The launch follows the companies' September 2026 introduction of research-grade Streptococcus pyogenes Cas9 mRNA in wild-type and SpyFi high-fidelity formats. That mRNA is compatible with electroporation, cationic lipids, and lipid nanoparticles.¹,³ At that time, the companies said base and prime editors would follow later in the year. They also described a path for customers moving from early research to
Regulators are also adapting to precision editing approaches. In October 2026, FDA issued draft guidance outlining how sponsors can submit a single biologics license application for individualized genome editing products tailored to each patient's genetic variant.⁴ The draft would allow new patient-specific
The newly launched products are research grade and intended for research use only, not for diagnostic or therapeutic procedures.¹ The announcement contained no performance data and directed users to product documentation. The companies also did not disclose timelines for CGMP versions of the base and prime editing mRNAs.
